Castle Biosciences stock
CSTLNASDAQCastle Biosciences, Inc., HealthcareISIN US14843C1053
43Score 43 out of 100, Weak
Price and trend
71 / 100
Price history
−0.9% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 20% below its 52-week high. Largest decline in 7 years: 88% (February 2021 to June 2023).
Chart figures for advanced users
- SMA 50$34.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$28.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.15
- The lowest closing price of the last twelve months.
- Resistance$43.04
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Castle Biosciences, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $1.06B, is number 34 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $344.23M (up 3.7% year on year) and a loss of $24.16M.
- For fiscal 2026, analysts expect on average revenue of $380.69M (up 10.6%) and adjusted earnings per share of −$1.04.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 498 of 714 in Healthcare, median 53.
- Our model puts fair value at $23.83, with the price 43% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 40.6% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 63
- More cash than debtCash $277.67M, financial debt $36.57M.Stability 56
Weaknesses
- DilutionShare count up 53% since 2020.Capital allocation 18
- Loss-makingLoss of $23.01M over the last 12 months.Fundamentals 18
- Volatile share priceVolatility 54% a year over the last 12 months.Stability 56
Its standout strength is technical analysis, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $17.02 and expensive above $39.71 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $19.61, at 8.2% it would be $30.01.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 9.8% on the twelve months before. Revenue has grown strongly since 2017, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating −12%, net −7%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported −$0.13 (expected −$0.35)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 27.1% since 15 Oct 2026.
- Earnings per share
- −$1.04+17.7%
- Revenue
- $380.69M+2.0%
- Earnings per share
- −$0.67+27.1%
- Revenue
- $427.46M+3.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +14.5%2026 revenue guidance raised to $365 million to $375 million, from $345 million to $355 million; adjusted gross margin in the low to mid 70s maintained.
“We believe we will continue this positive momentum in the second half of 2026, and our strong second quarter performance gives us the confidence to raise our 2026 total revenue guidance to $365 million to $375 million compared to the previously provided guidance of $345 million to $355 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $10.6M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Juvenal Tobin WSale
11 Nov 2026, Chief Commercial Officer
- Shares
- 2,828
- Price
- $35.04
- Value
- $99,104
- Juvenal Tobin WSale
9 Nov 2026, Chief Commercial Officer
- Shares
- 3,288
- Price
- $32.67
- Value
- $107,419
- Maetzold Derek JSale
2 Nov 2026, Pres. & Chief Exec. Officer
- Shares
- 14,496
- Price
- $36.10
- Value
- $523,330
Show 36 more
- Juvenal Tobin WSale
28 Oct 2026, Chief Commercial Officer
- Shares
- 6,578
- Price
- $36.42
- Value
- $239,591
- Juvenal Tobin WSale
26 Oct 2026, Chief Commercial Officer
- Shares
- 3,288
- Price
- $33.08
- Value
- $108,767
- Maetzold Derek JSale
19 Oct 2026, Pres. & Chief Exec. Officer
- Shares
- 14,496
- Price
- $31.91
- Value
- $462,567
- Juvenal Tobin WSale
12 Oct 2026, Chief Commercial Officer
- Shares
- 3,288
- Price
- $33.64
- Value
- $110,608
- Maetzold Derek JSale
5 Oct 2026, Pres. & Chief Exec. Officer
- Shares
- 14,496
- Price
- $35.57
- Value
- $515,565
- Oelschlager Kristen MSale
1 Oct 2026, Chief Operating Officer
- Shares
- 4,153
- Price
- $35.95
- Value
- $149,318
- Juvenal Tobin WSale
30 Sept 2026, Chief Commercial Officer
- Shares
- 1,034
- Price
- $34.20
- Value
- $35,363
- Juvenal Tobin WSale
29 Sept 2026, Chief Commercial Officer
- Shares
- 5,543
- Price
- $35.50
- Value
- $196,765
- Maetzold Derek JSale
21 Sept 2026, Pres. & Chief Exec. Officer
- Shares
- 14,496
- Price
- $35.33
- Value
- $512,202
- Juvenal Tobin WSale
15 Sept 2026, Chief Commercial Officer
- Shares
- 3,294
- Price
- $35.14
- Value
- $115,758
- Juvenal Tobin WSale
14 Sept 2026, Chief Commercial Officer
- Shares
- 3,306
- Price
- $32.32
- Value
- $106,863
- Maetzold Derek JSale
11 Sept 2026, Pres. & Chief Exec. Officer
- Shares
- 14,518
- Price
- $32.02
- Value
- $464,870
- Oelschlager Kristen MSale
1 Sept 2026, Chief Operating Officer
- Shares
- 4,152
- Price
- $33.39
- Value
- $138,643
- Juvenal Tobin WSale
31 Aug 2026, Chief Commercial Officer
- Shares
- 1,730
- Price
- $32.81
- Value
- $56,761
- Maetzold Derek JSale
28 Aug 2026, Pres. & Chief Exec. Officer
- Shares
- 17,726
- Price
- $33.20
- Value
- $588,448
- Juvenal Tobin WSale
25 Aug 2026, Chief Commercial Officer
- Shares
- 9,050
- Price
- $35.04
- Value
- $317,112
- Oelschlager Kristen MSale
25 Aug 2026, Chief Operating Officer
- Shares
- 12,384
- Price
- $34.42
- Value
- $426,277
- Oelschlager Kristen MSale
24 Aug 2026, Chief Operating Officer
- Shares
- 12,218
- Price
- $33.69
- Value
- $411,588
- Juvenal Tobin WSale
17 Aug 2026, Chief Commercial Officer
- Shares
- 1,730
- Price
- $29.59
- Value
- $51,191
- Stokes FrankSale
14 Aug 2026, Chief Financial Officer
- Shares
- 24,908
- Price
- $29.77
- Value
- $741,511
- Maetzold Derek JSale
14 Aug 2026, Pres. & Chief Exec. Officer
- Shares
- 6,398
- Price
- $30.02
- Value
- $192,068
- Maetzold Derek JSale
5 Aug 2026, Pres. & Chief Exec. Officer
- Shares
- 3,575
- Price
- $30.68
- Value
- $109,685
- Maetzold Derek JSale
4 Aug 2026, Pres. & Chief Exec. Officer
- Shares
- 35,441
- Price
- $31.11
- Value
- $1.1M
- Oelschlager Kristen MSale
3 Aug 2026, Chief Operating Officer
- Shares
- 8,586
- Price
- $29.77
- Value
- $255,622
- Juvenal Tobin WSale
3 Aug 2026, Chief Commercial Officer
- Shares
- 1,730
- Price
- $28.25
- Value
- $48,873
- Maetzold Derek JSale
3 Aug 2026, Pres. & Chief Exec. Officer
- Shares
- 18,493
- Price
- $30.35
- Value
- $561,318
- Juvenal Tobin WSale
31 Jul 2026, Chief Commercial Officer
- Shares
- 17,310
- Price
- $29.31
- Value
- $507,302
- Maetzold Derek JSale
31 Jul 2026, Pres. & Chief Exec. Officer
- Shares
- 10,153
- Price
- $30.15
- Value
- $306,133
- Maetzold Derek JSale
27 Jul 2026, Pres. & Chief Exec. Officer
- Shares
- 9,002
- Price
- $24.16
- Value
- $217,530
- Maetzold Derek JSale
14 Jul 2026, Pres. & Chief Exec. Officer
- Shares
- 3,338
- Price
- $22.92
- Value
- $76,507
- Maetzold Derek JSale
1 Jul 2026, Pres. & Chief Exec. Officer
- Shares
- 9,002
- Price
- $24.29
- Value
- $218,659
- Oelschlager Kristen MSale
1 Jul 2026, Chief Operating Officer
- Shares
- 8,586
- Price
- $24.42
- Value
- $209,650
- Oelschlager Kristen MSale
16 Jun 2026, Chief Operating Officer
- Shares
- 8,587
- Price
- $20.71
- Value
- $177,837
- Maetzold Derek JSale
15 Jun 2026, Pres. & Chief Exec. Officer
- Shares
- 3,338
- Price
- $20.66
- Value
- $68,963
- Maetzold Derek JSale
21 May 2026, Pres. & Chief Exec. Officer
- Shares
- 2,547
- Price
- $20.20
- Value
- $51,439
- Maetzold Derek JSale
20 May 2026, Pres. & Chief Exec. Officer
- Shares
- 791
- Price
- $20.00
- Value
- $15,822
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Castle Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- NeoGenomicsNEO $2.19B40
- VeracyteVCYT $2.03B53
- PersonalisPSNL $1.73B41
- GeneDx HoldingsWGS $1.64B37
- OPKO HealthOPK $1.27B37
- Fulgent GeneticsFLGT $718.03M36
- Myriad GeneticsMYGN $548.67M40
- VoxelVOX.WA $400.7M82
ETFs that hold Castle Biosciences
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.10% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.07% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.35% | €434.1M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.